CLINICAL_TRIALS
approval
· 2025-11-10
Clinical Trial Update: Compassionate Use of Pozelimab
Summary
Pozelimab has been approved for marketing for CD55-deficient Protein-losing Enteropathy under compassionate-use provisions.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Regeneron Pharmaceuticals | Conditions: CD55-deficient Protein-losing Enteropathy | Status: APPROVED_FOR_MARKETING